Patents by Inventor Richard M. Ransohoff

Richard M. Ransohoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HSPA5 ANTIBODIES AND USES THEREOF
    Publication number: 20210301002
    Abstract: This disclosure provides anti-HSPA5 antibodies. Also featured is a method for delivering an agent into the brain, spinal cord, or other component of the central nervous system. In addition, methods of identifying a human subject at risk of relapse of neuromyelitis optica (NMO) or neuropsychiatric systemic lupus erythematosus (NP-SLE) are disclosed, as are methods of determining the severity of an attack of NMO or NP-SLE, and methods of diagnosing NP-SLE.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 30, 2021
    Applicants: Biogen MA Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Jeffrey L. Bennett, Richard M. Ransohoff, Fumitaka Shimizu, Kristin L. Schaller
  • ANTI-HSPA5 (GRP78) ANTIBODIES AND USES THEREOF
    Publication number: 20190330318
    Abstract: This disclosure provides anti-HSPA5 antibodies. Also featured is a method for delivering an agent into the brain, spinal cord, or other component of the central nervous system. In addition, methods of identifying a human subject at risk of relapse of neuromyelitis optica (NMO) or neuropsychiatric systemic lupus erythematosus (NP-SLE) are disclosed, as are methods of determining the severity of an attack of NMO or NP-SLE, and methods of diagnosing NP-SLE.
    Type: Application
    Filed: July 24, 2017
    Publication date: October 31, 2019
    Inventors: Jeffrey L. Bennett, Richard M. Ransohoff, Fumitaka Shimizu, Kristin L. Schaller
  • Method for Predicting a Therapy Response in Subjects with Multiple Sclerosis
    Publication number: 20130089519
    Abstract: A method is provided for determining the efficacy of interferon-beta (IFN-?) therapy in a subject with multiple sclerosis. One step of the method can include obtaining a biological sample from the subject. After obtaining the biological sample, the expression level of at least one interferon-regulated gene (IRG) and/or variant thereof can be determined. Increased or decreased expression of the at least one IRG and/or variant thereof as compared to a control may indicate that the subject will respond poorly to IFN-? therapy.
    Type: Application
    Filed: June 17, 2011
    Publication date: April 11, 2013
    Inventors: Richard A. Rudick, Richard M. Ransohoff